FY2025 EPS Estimates for TSE:CPH Decreased by Analyst

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) – Analysts at Leede Financial lowered their FY2025 EPS estimates for Cipher Pharmaceuticals in a note issued to investors on Wednesday, March 19th. Leede Financial analyst D. Loe now anticipates that the company will earn $0.87 per share for the year, down from their prior estimate of $0.93. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.29 per share. Leede Financial also issued estimates for Cipher Pharmaceuticals’ FY2026 earnings at $1.00 EPS.

Cipher Pharmaceuticals Trading Down 2.6 %

Shares of CPH opened at C$13.14 on Friday. The company has a current ratio of 2.00, a quick ratio of 2.67 and a debt-to-equity ratio of 41.22. Cipher Pharmaceuticals has a 12-month low of C$7.90 and a 12-month high of C$19.69. The firm has a 50-day moving average price of C$12.91 and a 200 day moving average price of C$14.49. The firm has a market capitalization of C$235.91 million, a P/E ratio of 14.51 and a beta of 1.20.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company’s geographical segments include Canada and the United States.